Guide

Best Peptides for Fat Loss: A Research-Based Guide (2026)

Last updated: April 14, 2026 · 16 min read · Reviewed by Grey Peptides Editorial Board

TL;DR

The most effective peptides for fat loss fall into three categories: GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) that suppress appetite and improve metabolic signaling — these are the heavyweights with extensive clinical trial data; growth hormone secretagogues (CJC-1295/Ipamorelin, Tesamorelin) that increase natural GH production, which mobilizes stored body fat for energy; and the GH fragment AOD-9604, which isolates the fat-burning portion of growth hormone without its full hormonal effects. Semaglutide and tirzepatide are FDA-approved and the most proven options. GH secretagogues are slower-acting but improve body composition without the appetite suppression side effects of GLP-1 drugs.

→ Build a fat loss peptide protocol tailored to your goals in the Protocol Builder.

→ Compare any two fat loss peptides side-by-side in the Comparison Tool.

Table of Contents

  1. How Peptides Promote Fat Loss
  2. The 7 Best Peptides for Fat Loss (Ranked)
  3. Quick Comparison Table
  4. Detailed Breakdown: Each Peptide
  5. Best Peptide Stacks for Fat Loss
  6. Peptides vs Traditional Weight Loss Methods
  7. What to Expect: Realistic Timelines
  8. Important Considerations & Side Effects
  9. Frequently Asked Questions
  10. Sources

How Peptides Promote Fat Loss

Peptides reduce body fat through four distinct biological mechanisms. Understanding which mechanism each peptide uses is essential for choosing the right compound — or combination — for your situation.

Mechanism 1: Appetite Suppression (GLP-1 Pathway)

GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) mimic the incretin hormone GLP-1, which signals satiety to the brain. The result is a significant reduction in hunger, food cravings, and overall caloric intake. These compounds also slow gastric emptying (food stays in the stomach longer, prolonging fullness) and improve insulin sensitivity. This mechanism produces the largest and most rapid fat loss of any peptide category because it directly reduces caloric intake — the primary driver of body composition change.

Mechanism 2: Growth Hormone Optimization

GH secretagogues (CJC-1295, Ipamorelin, Sermorelin, Tesamorelin) stimulate the pituitary gland to release more natural growth hormone. Elevated GH increases lipolysis — the breakdown of stored triglycerides in fat cells into free fatty acids that can be oxidized for energy. GH also promotes lean mass retention during caloric deficit, improves sleep quality (which supports metabolic health), and enhances exercise recovery. This pathway is slower than GLP-1 suppression but produces favorable body recomposition — fat loss with muscle preservation.

Mechanism 3: Direct Lipolytic Fragment

AOD-9604 is a modified fragment of human growth hormone (amino acids 176–191) that retains GH's fat-metabolizing activity without its growth-promoting or diabetogenic effects. It directly stimulates lipolysis and inhibits lipogenesis (the formation of new fat) without affecting blood glucose or IGF-1 levels. Its selectivity makes it an attractive option for fat loss without the broader hormonal shifts of full GH stimulation.

Mechanism 4: Metabolic Enhancement

Some peptides influence fat loss indirectly through metabolic improvement. MOTS-c, a mitochondrial-derived peptide, activates AMPK (the cellular energy sensor) and improves mitochondrial function, enhancing the body's ability to oxidize fat for energy. This category is less established clinically but represents a growing area of research.

→ Understand the science behind these mechanisms at the Peptide Glossary — look up lipolysis, GLP-1, AMPK, and angiogenesis.

The 7 Best Peptides for Fat Loss (Ranked)

Quick Comparison Table

RankPeptideMechanismFat Loss StrengthRouteFrequencyHuman Data
1SemaglutideGLP-1 agonistVery StrongSubQWeeklyExtensive (FDA approved)
2TirzepatideGLP-1/GIP dual agonistVery StrongSubQWeeklyExtensive (FDA approved)
3RetatrutideGLP-1/GIP/Glucagon triple agonistVery StrongSubQWeeklyPhase II
4TesamorelinGHRH analog (GH release)ModerateSubQDailyFDA approved (lipodystrophy)
5CJC-1295 + IpamorelinGH secretagogue stackModerateSubQDaily (bedtime)Limited
6AOD-9604GH fragment (lipolysis)Mild–ModerateSubQDailyPhase II (inconclusive)
7MOTS-cMitochondrial peptide (AMPK)MildSubQ3–5x/weekVery limited

→ Run your own side-by-side analysis in the Comparison Tool.

Detailed Breakdown: Each Peptide

1. Semaglutide — The Proven Leader

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic) and subsequently approved for chronic weight management (Wegovy) at higher doses. It is the most extensively studied weight loss peptide in history, with clinical trial data from the STEP program involving over 10,000 participants.

How it works. Semaglutide mimics the incretin hormone GLP-1 with structural modifications that extend its half-life to approximately 7 days, enabling once-weekly dosing. It binds GLP-1 receptors in the hypothalamus (reducing appetite), the gut (slowing gastric emptying), and the pancreas (improving insulin secretion). The primary fat loss mechanism is sustained appetite suppression — participants in clinical trials consistently ate 20–35% fewer calories without conscious effort. [1]

Clinical results. The STEP 1 trial demonstrated an average weight loss of approximately 15% of body weight over 68 weeks at the 2.4 mg weekly dose in adults without diabetes. The STEP 5 extension study showed sustained weight loss over 2 years with continued use. [2]

Dosing. The standard titration schedule starts at 0.25 mg weekly for 4 weeks, increasing by 0.25 mg every 4 weeks until reaching the target dose of 1.7–2.4 mg weekly. Slow titration minimizes GI side effects.

Side effects. Nausea (most common, usually transient), constipation, diarrhea, vomiting, and abdominal discomfort. Most GI effects diminish within the first 4–8 weeks as the body adjusts.

Availability. FDA-approved as Ozempic (diabetes) and Wegovy (weight management). Also available from compounding pharmacies, though the FDA has issued warnings about some compounded versions.

2. Tirzepatide — The Dual Agonist

Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, making it the first dual incretin agonist. This dual mechanism appears to produce modestly greater weight loss than semaglutide alone in head-to-head trials.

How it works. By activating both GLP-1 and GIP receptors simultaneously, tirzepatide produces appetite suppression (GLP-1) combined with enhanced fat mobilization and improved insulin sensitivity (GIP). The GIP component appears to independently promote adipose tissue remodeling and energy expenditure. [3]

Clinical results. The SURMOUNT-1 trial demonstrated average weight loss of approximately 21% of body weight at the highest dose (15 mg weekly) over 72 weeks — the largest weight reduction achieved by any pharmaceutical agent in clinical trials. [4]

Dosing. Starts at 2.5 mg weekly, increasing by 2.5 mg every 4 weeks to a target of 10–15 mg weekly.

Side effects. Similar GI profile to semaglutide. Some data suggests GI tolerability may be slightly better due to the GIP component's moderating influence.

Availability. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management).

3. Retatrutide — The Triple Agonist

Retatrutide is a next-generation investigational peptide that activates three receptors: GLP-1, GIP, and glucagon. The addition of glucagon receptor agonism adds direct fat-burning activity, as glucagon is one of the body's primary signals for mobilizing and oxidizing stored fat.

How it works. The triple-agonist approach combines appetite suppression (GLP-1), metabolic improvement (GIP), and direct lipolysis stimulation (glucagon). The glucagon component also increases energy expenditure, potentially creating a "fat-burning" effect independent of caloric reduction. [5]

Clinical results. Phase II trial data showed average weight loss of approximately 24% of body weight at the highest dose over 48 weeks — exceeding even tirzepatide's results, though direct comparison requires Phase III data. [6]

Dosing. Phase II used doses ranging from 1 mg to 12 mg weekly, with the highest efficacy at 8–12 mg.

Availability. Investigational only. Phase III trials are ongoing. Not yet available through pharmacies or compounding.

4. Tesamorelin — FDA-Approved GH Peptide

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates natural GH production from the pituitary. It is FDA-approved specifically for reducing excess abdominal fat (lipodystrophy) in HIV patients but is used off-label for body composition optimization.

How it works. By stimulating pulsatile GH release, tesamorelin increases lipolysis (particularly in visceral adipose tissue), improves body composition, and may reduce liver fat. Unlike exogenous GH, it preserves the body's natural feedback mechanisms — GH levels rise but remain within physiological ranges. [7]

Clinical results. FDA approval studies showed significant reduction in visceral adipose tissue (approximately 15–18% reduction in trunk fat) over 26 weeks. Body composition improved with fat loss concentrated in the abdominal region. [8]

Dosing. 2 mg injected subcutaneously once daily, typically in the morning.

Side effects. Injection site reactions, joint pain, peripheral edema. Generally well-tolerated.

Availability. FDA-approved as Egrifta SV. Available by prescription. Also available from compounding pharmacies for off-label use.

5. CJC-1295 + Ipamorelin — The GH Secretagogue Stack

This combination pairs a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) to stimulate GH release through two different pituitary pathways simultaneously. It is the most widely used GH secretagogue combination in peptide therapy clinics.

How it works. CJC-1295 (with or without DAC) acts on GHRH receptors to amplify the signal for GH release. Ipamorelin acts on ghrelin (GHS-R) receptors as a secondary trigger. Together, they produce a stronger, more sustained GH pulse than either compound alone. Elevated GH drives lipolysis, lean mass retention, and improved sleep quality. [9]

Expected results. Body composition changes are more gradual than GLP-1 agents — typically 1–2 pounds of fat loss per month with improved lean mass, visible over 3–6 months. The primary benefits are body recomposition (simultaneous fat loss and muscle preservation), improved sleep, and enhanced recovery from exercise.

Dosing. CJC-1295 (no DAC): 100 mcg + Ipamorelin: 100–200 mcg, injected subcutaneously at bedtime on an empty stomach, 5–7 nights per week.

Side effects. Transient flushing, water retention (usually mild), increased hunger (from Ipamorelin's ghrelin mimetic activity), tingling in extremities.

→ Full protocol details: CJC-1295 + Ipamorelin Stack Guide.

6. AOD-9604 — The Fat-Specific Fragment

AOD-9604 is a modified fragment of human growth hormone consisting of amino acids 176–191 from the C-terminal region — the portion of the GH molecule responsible for fat metabolism — with an additional tyrosine amino acid added.

How it works. AOD-9604 stimulates lipolysis and inhibits lipogenesis through the beta-3 adrenergic receptor pathway, mimicking the fat-metabolizing action of natural GH. Critically, it does not affect blood glucose, does not stimulate IGF-1 production, and does not promote tissue or bone growth — isolating the fat-specific effects of GH. [10]

Clinical results. Phase II clinical trial results were mixed. A 2010 study showed statistically significant weight loss versus placebo, but the magnitude was modest (approximately 2.8 kg over 12 weeks). The compound was not advanced to Phase III, raising questions about its standalone efficacy. [11]

Dosing. 250–300 mcg injected subcutaneously once daily, typically in the morning on an empty stomach.

Side effects. Minimal reported side effects. Injection site reactions, occasional headache.

Availability. Available from compounding pharmacies and research suppliers. TGA-approved in Australia for over-the-counter sale in certain formulations.

7. MOTS-c — The Mitochondrial Exercise Mimetic

MOTS-c is a mitochondrial-derived peptide (encoded within the mitochondrial genome, not the nuclear genome) that functions as an exercise mimetic — it activates many of the same metabolic pathways that physical exercise activates.

How it works. MOTS-c activates AMPK (AMP-activated protein kinase), the master cellular energy sensor, which increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis. It essentially signals cells to burn more fat and improve their metabolic efficiency — similar to the metabolic benefits of regular endurance exercise. [12]

Clinical results. Very limited human data. Early studies suggest improvements in insulin sensitivity and metabolic markers. Fat loss data in humans is not yet available from controlled trials.

Dosing. 5–10 mg injected subcutaneously 3–5 times per week. Dosing protocols are not well established.

Side effects. Limited safety data. Injection site reactions reported. Long-term effects unknown.

Availability. Research compound only. Available from research peptide suppliers.

Best Peptide Stacks for Fat Loss

Stack 1: GLP-1 + GH Secretagogue (Maximum Recomposition)

Components: Semaglutide (or tirzepatide) + CJC-1295/Ipamorelin

Rationale: The GLP-1 agent drives caloric reduction through appetite suppression, while the GH secretagogue maximizes fat mobilization and protects lean mass during the caloric deficit. The GH component also improves sleep quality and recovery, supporting the energy and exercise capacity needed for sustained fat loss.

Timing: GLP-1 agent — once weekly (any time). CJC-1295/Ipamorelin — nightly before bed, empty stomach.

Who it's for: Individuals seeking significant weight loss (20+ lbs) while preserving or building lean mass.

Stack 2: CJC-1295/Ipamorelin + AOD-9604 (Non-GLP-1 Approach)

Components: CJC-1295/Ipamorelin (bedtime) + AOD-9604 (morning)

Rationale: For those who want to avoid GLP-1 agents (due to GI side effects, cost, or preference), this stack combines two different fat-mobilizing mechanisms — pulsatile GH release at night and direct lipolytic fragment activity during the day. Results are more gradual than GLP-1 approaches but avoid the appetite suppression that some people find uncomfortable.

Timing: AOD-9604 — morning, empty stomach. CJC-1295/Ipamorelin — bedtime, empty stomach.

Who it's for: Individuals seeking moderate, gradual body recomposition without appetite changes.

Stack 3: Fat Loss + Recovery (Recomposition + Repair)

Components: Tirzepatide + BPC-157

Rationale: GLP-1 agents can sometimes impair exercise performance due to reduced caloric intake and GI effects. Adding BPC-157 supports recovery from training, protects the GI tract (which GLP-1 agents stress), and may support connective tissue integrity during weight loss. This stack is particularly relevant for active individuals maintaining intense training programs during a cut.

Timing: Tirzepatide — once weekly. BPC-157 — twice daily (morning + evening) SubQ.

→ Check any peptide combination for safety and timing conflicts in the Interaction Checker.

→ Build a complete fat loss stack protocol in the Protocol Builder.

Peptides vs Traditional Weight Loss Methods

Peptides are not a replacement for the fundamentals of fat loss — caloric deficit, regular exercise, adequate sleep, and stress management. They are tools that can make these fundamentals easier, more effective, or faster.

GLP-1 agents vs diet alone. Clinical trial data consistently shows that semaglutide and tirzepatide produce significantly greater weight loss than lifestyle intervention alone. However, weight regain after discontinuation is common — the STEP 1 extension data showed approximately two-thirds of weight loss was regained within one year of stopping semaglutide. This underscores that these are tools that work alongside behavior change, not substitutes for it. [13]

GH secretagogues vs exercise. GH peptides cannot replicate the full metabolic, cardiovascular, and psychological benefits of regular exercise. They optimize the hormonal environment for fat loss and recovery, but exercise remains irreplaceable for long-term metabolic health.

Cost comparison. GLP-1 agents are expensive — brand-name semaglutide and tirzepatide can exceed $1,000/month without insurance. Compounded versions are less costly but face ongoing regulatory scrutiny. GH secretagogues from compounding pharmacies typically run $150–400/month. AOD-9604 and MOTS-c are less expensive. These costs should be weighed against gym memberships, nutrition coaching, and other fat-loss investments.

→ Estimate your monthly costs for any fat loss protocol with the Cost Calculator.

What to Expect: Realistic Timelines

Peptide CategoryFirst Noticeable EffectsSignificant ResultsPeak Results
GLP-1 agonists1–2 weeks (appetite change)8–12 weeks (visible fat loss)6–12 months
GH secretagogues2–4 weeks (sleep, recovery)8–16 weeks (body composition)4–6 months
AOD-96044–6 weeks8–12 weeks3–4 months
MOTS-c4–8 weeks12–16 weeksUnknown

Set expectations correctly. Even the most powerful GLP-1 agents take months to produce their full effect. The dramatic before-and-after photos popular on social media typically represent 6–12 months of consistent use combined with lifestyle changes. There are no overnight results in fat loss — peptide-assisted or otherwise.

Important Considerations & Side Effects

GLP-1 Agent Considerations

Gastrointestinal effects (nausea, constipation, diarrhea) are the most common reason people discontinue GLP-1 agents. Slow dose titration minimizes these effects for most users. More serious but rare concerns include pancreatitis risk, gallbladder complications, and a theoretical thyroid concern based on rodent data (medullary thyroid carcinoma — observed in rats at very high doses but not confirmed in humans). [14]

Muscle loss during rapid weight loss is a documented concern with GLP-1 agents. The caloric deficit they create can cause loss of lean mass alongside fat mass. Resistance training and adequate protein intake (1.0–1.2 g/kg body weight minimum) are critical countermeasures. Adding a GH secretagogue to the protocol may provide additional lean mass preservation.

GH Secretagogue Considerations

Water retention is common in the first 2–4 weeks and can mask fat loss on the scale. Joint stiffness and carpal tunnel-like symptoms may occur at higher doses. Blood sugar should be monitored, as GH can induce insulin resistance at supraphysiological levels.

General Peptide Considerations

No peptide is a substitute for the foundations of fat loss. A caloric deficit (through reduced intake or increased expenditure), resistance training, adequate protein, quality sleep, and stress management remain the primary drivers. Peptides accelerate and enhance these fundamentals — they do not replace them.

Frequently Asked Questions

Which peptide causes the most fat loss? By clinical trial data, tirzepatide at 15 mg weekly produces the greatest average fat loss of any peptide — approximately 21% of body weight over 72 weeks. Retatrutide may exceed this based on Phase II data, but Phase III confirmation is pending.

Can I use fat loss peptides without exercise? Yes — GLP-1 agents produce significant fat loss even without structured exercise in clinical trials. However, exercise dramatically improves outcomes: it preserves lean mass, prevents metabolic adaptation, improves cardiovascular health, and supports weight maintenance after discontinuation.

Are fat loss peptides safe long-term? Semaglutide and tirzepatide have multi-year safety data from clinical trials and real-world use. Long-term data (10+ years) is not yet available as these compounds are relatively new. GH secretagogues and research peptides have much less safety data. Discuss long-term use with your healthcare provider.

Will I regain weight when I stop? With GLP-1 agents, weight regain after discontinuation is common — approximately 60–70% of lost weight in the first year off treatment. This is a biological response to the removal of the appetite-suppressing signal. Sustainable lifestyle changes during treatment are essential for long-term maintenance.

Can I use fat loss peptides if I have diabetes? Semaglutide and tirzepatide are actually FDA-approved for type 2 diabetes and can be beneficial. However, they require careful blood sugar monitoring and medication adjustment. GH secretagogues can worsen insulin resistance at high doses. Always work with your physician.

What's the most cost-effective fat loss peptide? CJC-1295/Ipamorelin from a compounding pharmacy typically costs $150–300/month and provides body recomposition benefits alongside fat loss. AOD-9604 is also relatively affordable at $100–200/month. GLP-1 agents are the most expensive but produce the most dramatic results.

Sources

  1. Wilding, J. P. H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. PMID: 33567185
  2. Garvey, W. T. et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. PMID: 36216945
  3. Jastreboff, A. M. et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. PMID: 35658024
  4. Jastreboff, A. M. et al. (2022). SURMOUNT-1: Tirzepatide for obesity — Phase III results. New England Journal of Medicine, 387(3), 205–216. PMID: 35658024
  5. Jastreboff, A. M. et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. New England Journal of Medicine, 389(6), 514–526. PMID: 37385268
  6. Jastreboff, A. M. et al. (2023). Retatrutide Phase 2 obesity trial results. New England Journal of Medicine, 389(6), 514–526. PMID: 37385268
  7. Stanley, T. L. et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA, 312(4), 380–389. PMID: 25038357
  8. Falutz, J. et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. PMID: 18057338
  9. Ionescu, M. & Bhatt, D. (2015). Growth hormone secretagogues: clinical applications and mechanisms. Endocrine Practice, 21(Suppl 2), 75–86.
  10. Heffernan, M. et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3AR knock-out mice. Endocrinology, 142(12), 5182–5189. PMID: 11713213
  11. Stier, H. et al. (2013). AOD-9604 Phase IIb trial data. Obesity Research & Clinical Practice, 7(2), 147–154.
  12. Lee, C. et al. (2015). MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Cell Metabolism, 21(3), 443–454. PMID: 25738459
  13. Wilding, J. P. H. et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. PMID: 35441470
  14. FDA. (2023). Semaglutide (Wegovy) prescribing information. U.S. Food and Drug Administration.

Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Weight management peptides — particularly GLP-1 receptor agonists — are prescription medications that require medical supervision. Do not begin any weight loss peptide protocol without consulting a licensed healthcare provider who can assess your individual health status, risks, and goals.

© 2026 GreyPeptides.com — All rights reserved.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Consult a licensed medical professional before considering any peptide therapy.

← All articles